Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2)

Mise à jour : Il y a 4 ans
Référence : NCT00886353

Femme et Homme

  • | Pays :
  • Switzerland
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The purpose of this study is to define the dose for a Phase II study and to investigate safety and tolerability of intravenous administration of recombinant soluble human Angiotensin Converting Enzyme 2 in healthy volunteers.


Critère d'inclusion

  • Pulmonary diseases ,Cardiovascular Diseases ,Kidney Diseases ,Cancer Diseases

Liens